XML 93 R83.htm IDEA: XBRL DOCUMENT v3.25.4
Stockholders' Equity - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2023
Sep. 01, 2024
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Apr. 30, 2025
Jun. 12, 2024
Apr. 30, 2024
Mar. 31, 2024
Dec. 06, 2023
May 31, 2023
Dec. 31, 2018
Stockholders Equity Note Disclosure [Line Items]                        
Common stock, shares issued     56,325,429 56,091,677                
Stock-based compensation expense   $ 22,400 $ 32,605 $ 48,070 $ 25,575              
Stock options, outstanding     563,273 596,206                
Restricted stock units, outstanding     555,047 470,612                
Aggregate intrinsic value of stock options exercised     $ 8,225 $ 10,400 $ 5,800              
Weighted average grant date fair value of share-based awards granted     $ 73.38 $ 88 $ 84.37              
Weighted average grant date fair value of restricted stock units granted     $ 144.73                  
Total unrecognized compensation cost     $ 63,700                  
Unrecognized compensation cost, weighted average remaining requisite service period     2 years 7 months 6 days                  
Forfeited portion of grants     18,279                  
Share recalculated value             $ 136          
Avitide Llc                        
Stockholders Equity Note Disclosure [Line Items]                        
Common stock, shares issued           52,935   28,638     42,621  
FlexBiosys, Inc.                        
Stockholders Equity Note Disclosure [Line Items]                        
Common stock, shares issued           5,517     2,770      
2018 Plan                        
Stockholders Equity Note Disclosure [Line Items]                        
Common stock shares reserved for Issuance                       2,778,000
Incentive options, vesting period     1,194,241                  
Restricted Stock And Performance Stock Units [Member]                        
Stockholders Equity Note Disclosure [Line Items]                        
Aggregate intrinsic value of restricted stock units vested     $ 23,200 $ 26,700 $ 35,700              
Total grant date fair value of restricted stock units vested     $ 25,700 22,000 $ 26,200              
2024 Grants                        
Stockholders Equity Note Disclosure [Line Items]                        
Forfeited portion of grants     32,776                  
1.00% Convertible Senior Notes due 2028                        
Stockholders Equity Note Disclosure [Line Items]                        
Net proceeds from public offering $ 14,400                      
Repurchase of common stock (in shares) 92,090                      
Closing price of common stock $ 156.22       $ 156.22         $ 156.2    
Share repurchase amount $ 25,000       $ 25,000              
Aggregate principal amount $ 600,000   $ 600,000 $ 600,000 $ 600,000